Nkarta (NKTX) Other Non-Current Liabilities (2019 - 2026)

Nkarta's quarterly Other Non-Current Liabilities came in at $87000.0 in Q1 2026, little changed year-on-year from $87000.0 in Q1 2025, and little changed quarter-over-quarter from $87000.0 in Q4 2025.

Nkarta has reported Other Non-Current Liabilities for 7 years, with the latest figure at $87000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other Non-Current Liabilities changed 0.0% year-over-year to $87000.0; the trailing twelve-month figure through Mar 2026 stood at $87000.0 (changed 0.0% YoY), and the FY2025 full-year result was $87000.0, changed 0.0% from the prior year.
  • Other Non-Current Liabilities for Q1 2026 stood at $87000.0, roughly flat from $87000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $87000.0 in Q4 2024, with the low at $5000.0 in Q3 2022.
  • Average Other Non-Current Liabilities over 4 years is $60666.7, with a median of $87000.0 recorded in 2024.
  • Year-over-year, Other Non-Current Liabilities sank 91.07% in 2022 and changed 0.0% in 2025.
  • Tracing NKTX's Other Non-Current Liabilities over 4 years: stood at $5000.0 in 2022, then soared by 1640.0% to $87000.0 in 2024, then changed by 0.0% to $87000.0 in 2025, then changed by 0.0% to $87000.0 in 2026.
  • The last three Other Non-Current Liabilities figures came in at $87000.0 (Q1 2026), $87000.0 (Q4 2025), and $87000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Nkarta 232.80 Mn 232.80 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 87,000.00
Dec 31, 2025 87,000.00
Sep 30, 2025 87,000.00
Jun 30, 2025 87,000.00
Mar 31, 2025 87,000.00
Dec 31, 2024 87,000.00
Sep 30, 2022 5,000.00
Jun 30, 2022 8,000.00
Mar 31, 2022 11,000.00
Dec 31, 2021 18,000.00
Sep 30, 2021 56,000.00
Jun 30, 2021 65,000.00
Mar 31, 2021 75,000.00
Dec 31, 2020 82,000.00
Sep 30, 2020 96,000.00
Jun 30, 2020 119,963.00
Dec 31, 2019 134,000.00